USPTO Examiner CHUNDURU SURYAPRABHA - Art Unit 1637

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
16492032OLIGONUCLEOTIDES AND METHOD FOR THE DETECTION AND TYPING OF HUMAN PAPILLOMAVIRUSDecember 2020November 2023Abandon5001NoNo
17048244PRIMER SET FOR USE IN DETECTION OF CANDIDA AURIS, CANDIDA AURIS DETECTION KIT, AND CANDIDA AURIS DETECTION METHODOctober 2020April 2023Allow3021YesNo
17039865PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020March 2024Abandon4201NoNo
17003790TRANSCRIPTOME SEQUENCING THROUGH RANDOM LIGATIONAugust 2020March 2024Allow4340YesNo
16971513PRIMER SET FOR DETECTING TRICHOPHYTON GENE BY LAMP METHOD, KIT INCLUDING SAME, AND METHOD FOR DETECTING TRICHOPHYTON USING SAMEAugust 2020October 2022Allow2621YesNo
16967659REAGENT AND METHOD FOR FLUORESCENCE QUANTITATIVE REAL-TIME PCR DETECTION OF RCLAugust 2020February 2023Allow3011NoNo
16966839TARGET NUCLEIC ACID-DETECTING METHOD USING THREE-WAY JUNCTION STRUCTURE-INDUCED ISOTHERMAL AMPLIFICATIONJuly 2020May 2024Abandon4651YesNo
16966778TARGET NUCLEIC ACID-DETECTING METHOD USING HAIRPIN PROBE-ASSISTED ISOTHERMAL PROBE AMPLIFICATIONJuly 2020August 2024Abandon4851NoNo
16772714Method For The Simultaneous Detection And Quantification Of Epstein-Barr Virus, Cytomegalovirus, Human Herpesvirus 6, Human Herpesvirus 7 and Kaposi's Sarcoma Virus Using A Multiplex, Real-Time Polymerase Chain ReactionJuly 2020May 2024Allow4740YesNo
16963298METHODS, CONJUGATES AND SYSTEMSJuly 2020November 2023Abandon4001NoNo
16924204METHODS FOR LOADING A DIGITAL PCR CHIPJuly 2020April 2024Abandon4520YesYes
16958535METHOD FOR QUICKLY HOMOGENIZING CIRCULAR DNA SAMPLESJune 2020May 2022Abandon2211NoNo
15733317METHOD FOR RAPIDLY PREPARING SANGER SEQUENCING TEMPLATEJune 2020April 2022Abandon2210NoNo
16946376METHOD FOR SELECTION OF CORRECT NUCLEIC ACIDSJune 2020March 2022Abandon2110NoNo
16892638METHOD FOR ANALYZING NUCLEIC ACID SEQUENCEJune 2020November 2022Allow3020NoYes
16892612METHOD FOR ANALYZING NUCLEIC ACID SEQUENCEJune 2020November 2022Allow3020NoYes
16878791PRIMERS, KIT AND METHOD FOR DETECTING EHP PATHOGENS OF LITOPENAEUS VANNAMEIMay 2020June 2022Abandon2511NoNo
16870444COMPOSITIONS AND METHODS FOR IMPROVED cDNA SYNTHESISMay 2020December 2023Abandon4340YesNo
16760296NUCLEIC ACID QUANTIFICATION METHOD USING STABLE ISOTOPE-LABELLED NUCLEIC ACID AS INTERNAL STANDARD AND USE OF THE SAMEApril 2020August 2023Abandon4040YesNo
16756198DRY COMPOSITIONS FOR USE IN NUCLEIC ACID AMPLIFICATION AND METHODSApril 2020June 2022Abandon2611NoNo
16650677Onion Discrimination MethodMarch 2020September 2022Allow3041YesNo
16649659A METHOD OF AMPLIFYING A TARGET NUCLEIC ACIDMarch 2020January 2023Allow3420NoNo
16823731METHODS AND COMPOSITIONS FOR PREPARING POLYNUCLEOTIDESMarch 2020February 2023Allow3520NoNo
16816627METHODS OF DETECTING MINIMAL RESIDUAL DISEASEMarch 2020July 2022Abandon2810NoNo
16809280STABILIZED REDUCING AGENTS AND METHODS USING SAMEMarch 2020September 2021Abandon1901NoNo
16801254PHASE-PROTECTING REAGENT FLOW ORDERINGS FOR USE IN SEQUENCING-BY-SYNTHESISFebruary 2020March 2022Allow2521NoNo
16639662METHODS AND KITS FOR DETECTION OF NUCLEIC ACID MOLECULESFebruary 2020February 2024Abandon4851YesNo
16639422METHOD AND COMPOSITIONS FOR EVALUATING EMULSION UNIFORMITYFebruary 2020July 2023Abandon4130NoNo
16789287METHODS FOR PROCESSING NUCLEIC ACID MOLECULESFebruary 2020October 2022Allow3220NoNo
16637076METHOD FOR EVALUATING RISK OF HEPATOCELLULAR CARCINOMAFebruary 2020August 2023Abandon4330NoNo
16752875DNA SEQUENCINGJanuary 2020February 2022Allow2521NoNo
16633731METHOD OF ISOLATING NUCLEIC ACIDJanuary 2020May 2023Abandon4022NoNo
16750319CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAMEJanuary 2020January 2022Allow2320NoNo
16749731METHODS OF NUCLEIC ACID DETECTION AND PRIMER DESIGNJanuary 2020December 2023Abandon4740YesNo
16720065METHODS FOR DETECTING VARIANT NUCLEOTIDESDecember 2019May 2023Abandon4130NoYes
16624782PCR PRIMER PAIR AND APPLICATION THEREOFDecember 2019June 2024Allow5431NoYes
16719031DNA SEQUENCINGDecember 2019July 2022Abandon3021NoNo
16717704Methods And Kits For Detecting A Prostate Carcinoma And Predicting Disease Outcomes For Prostate CancersDecember 2019August 2022Abandon3210NoNo
16622122RT-QPCR METHOD FOR DIRECT QUANTITATIVE DETECTION OF CIRCULATING MIRNADecember 2019November 2022Abandon3520NoNo
16706243Assay for the Rapid Detection of Nucleic Acids via a Modified LAMP Reaction Coupled with Colorimetric Reporter Utilizing a Gold Nanoparticle Peptide Nucleic Acid AuNP-PNA Probe SystemDecember 2019August 2022Abandon3320NoNo
16703190METHODS FOR MULTIPLEXING RECOMBINASE POLYMERASE AMPLIFICATIONDecember 2019September 2022Allow3420NoNo
16700824Polynucleotides for Amplification and Detection of Human Beta ActinDecember 2019September 2023Allow4621NoNo
16693211SYSTEM AND KIT FOR DETECTING THE NUMBER OF CGG REPEATS IN THE 5' UNTRANSLATED REGION OF FMR1 GENENovember 2019May 2024Abandon5351NoNo
16688531METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIESNovember 2019December 2023Abandon4841YesNo
16658029Pyrophosphorolysis activated fluorescence to measure PAP amplification of nucleic acidOctober 2019January 2024Allow5150YesNo
16595167METHODS FOR PERFORMING MULTIPLEXED REAL-TIME PCROctober 2019September 2021Allow2310NoNo
16590878METHODS OF PREPARING NUCLEIC ACIDS FOR SEQUENCINGOctober 2019June 2023Allow4540YesNo
16588405DETERMINING 5' TRANSCRIPT SEQUENCESSeptember 2019January 2023Allow3941NoNo
16569081AMPLIFICATION METHOD OF A SINGLE STRANDED DNASeptember 2019March 2023Abandon4231YesNo
16492262NUCLEIC ACID ENZYME-MEDIATED SIGNAL AMPLIFICATION FOR BIOSENSINGSeptember 2019June 2024Abandon5851YesNo
16492084EASY ONE-STEP AMPLIFICATION AND LABELING (EOSAL)September 2019October 2021Abandon2501NoNo
16553667Method of enhancing isothermal amplification sensitivity of nucleic acid and reagents thereofAugust 2019November 2023Abandon5141NoNo
16543211Multiplex Preparation of Barcoded Gene Specific DNA FragmentsAugust 2019January 2022Allow2921NoNo
16485187PCR PRIMER SET FOR HLA GENE, AND SEQUENCING METHOD USING SAMEAugust 2019January 2022Abandon3011NoNo
16519506DETECTION OF TARGETED SEQUENCE REGIONSJuly 2019April 2022Allow3320NoNo
16474510REAGENT FOR USE IN ASSESSMENT OF REMAINING VERY SMALL LESION OF NEUROBLASTOMA; AND METHOD FOR ANALYZING BIOLOGICAL SAMPLE USING SAMEJune 2019July 2022Abandon3721NoNo
16473020METHOD FOR DIAGNOSING LUNG CANCER VIA BACTERIAL METAGENOMIC ANALYSISJune 2019November 2023Abandon5251NoNo
16434652METHOD AND SYSTEM FOR DIFFERENTIATING MORE PATHOGENIC STAPHYLOCOCCUS STRAINSJune 2019February 2022Abandon3211NoNo
16414672PRIMER PAIR, KIT AND METHOD OF DETECTING BABESIA CANISMay 2019November 2022Abandon4220NoNo
16349892NON-UNIQUE BARCODES IN A GENOTYPING ASSAYMay 2019September 2024Abandon6070NoNo
16345733STR BASED RAPID PERSONAL IDENTIFICATIONApril 2019September 2021Abandon2801NoNo
16370329METHOD FOR OBTAINING BASE SEQUENCE INFORMATION OF SINGLE CELL DERIVED FROM VERTEBRATEMarch 2019October 2021Abandon3010NoNo
16370342METHOD FOR DETERMINING ORIGIN OF HUMAN GENOMIC DNA OF 100 PG OR LESS, METHOD FOR IDENTIFYING INDIVIDUAL, AND METHOD FOR ANALYZING LEVEL OF ENGRAFTMENT OF HEMATOPOIETIC STEM CELLSMarch 2019October 2021Abandon3110NoNo
16099953POLYNUCLEOTIDE ENRICHMENT AND AMPLIFICATION USING CRISPR-CAS OR ARGONAUTE SYSTEMSMarch 2019September 2022Allow4640YesNo
16352083DIRECT-TO-CONSUMER GENOMIC DIAGNOSTIC DEVICEMarch 2019February 2022Abandon3511YesNo
16284030METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCEFebruary 2019October 2022Abandon4321NoNo
16321418Methods of Producing Amplified Double Stranded Deoxyribonucleic Acids and Compositions and Kits for Use ThereinJanuary 2019July 2022Allow4141YesNo
16224617ENHANCED NUCLEIC ACID IDENTIFICATION AND DETECTIONDecember 2018April 2022Allow4020YesNo
16223751DNA SEQUENCINGDecember 2018December 2023Abandon6061YesNo
16224444ITERATIVE NUCLEIC ACID ASSEMBLY USING ACTIVATION OF VECTOR-ENCODED TRAITSDecember 2018June 2023Abandon5331YesNo
16167893OPTIMIZED REAL-TIME NUCLEIC ACID DETECTION PROCESSESOctober 2018January 2022Abandon3920NoNo
16161203DETECTION ACCURACY IDENTIFYING METHOD, DETECTION ACCURACY IDENTIFYING DEVICE, AND NON-TRANSITORY RECORDING MEDIUM STORING DETECTION ACCURACY IDENTIFYING PROGRAMOctober 2018July 2024Abandon6041YesNo
16155133RECOMBINASE POLYMERASE AMPLIFICATIONOctober 2018February 2022Allow4011NoNo
16143085METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERSSeptember 2018April 2024Abandon6051NoYes
16088230Polarization-Based Fluorescent Nucleic Acid DetectionSeptember 2018June 2023Abandon5621NoNo
16079432LEUKEMIA DIAGNOSTIC KIT TARGETING PROHIBITIN GENE AND DIAGNOSTIC METHOD USING SAMEAugust 2018March 2022Allow4321NoNo
16057670Direct Capture, Amplification and Sequencing of Target DNA Using Immobilized PrimersAugust 2018August 2020Abandon2420NoNo
16048975SYSTEM AND METHOD FOR CAPTURING AND ANALYZING CELLSJuly 2018March 2022Allow4370YesNo
15973243DIGITAL ASSAYS WITH A GENERIC REPORTERMay 2018February 2022Allow4630NoYes
15941057ENDONUCLASE-ASSISTED ISOTHERMAL AMPLIFICATION USING CONTAMINATION-FREE REAGENTSMarch 2018October 2021Allow4321NoNo
15867115MEMBRANE ASSAY METHODJanuary 2018April 2022Allow5140NoNo
15740255PROBES AND A METHYLATION IN SITU HYBRIDIZATION ASSAYDecember 2017July 2019Abandon1801NoNo
15738821BIOSENSOR COMPRISING TANDEM REACTIONS OF STRUCTURE SWITCHING, NUCLEOLYTIC DIGESTION AND AMPLIFICATION OF A NUCLEIC ACID ASSEMBLYDecember 2017December 2019Abandon2411NoNo
15815230AMPLICON MELTING ANALYSIS WITH SATURATION DYESNovember 2017November 2020Abandon3640YesNo
15798696SEQUENCE, TECHNIQUE PLATFORM, AND METHOD FOR IN VITRO DETECTING CLOSTRIDIUM DIFFICILE RIBOTYPE 027October 2017February 2022Abandon5240YesNo
15784929Methods and Compositions for Rapid Multiplex Application of STR LOCIOctober 2017January 2021Allow3920YesNo
15566718Method for Analysing Nuclease Hypersensitive SitesOctober 2017August 2024Abandon6061NoYes
15705821METHODS FOR PERFORMING MULTIPLEXED REAL-TIME PCRSeptember 2017March 2021Allow4231NoNo
15705772METHODS FOR PERFORMING MULTIPLEXED PCRSeptember 2017February 2021Allow4130NoNo
15704159SIMULTANEOUS SEQUENCING OF RNA AND DNA FROM THE SAME SAMPLESeptember 2017June 2020Abandon3301NoNo
15691279HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODSAugust 2017October 2019Abandon2610NoNo
15689120DUAL POLARITY ANALYSIS OF NUCLEIC ACIDSAugust 2017July 2020Abandon3430NoNo
15658041METHODS AND MATERIALS FOR CAPTURE ANTIBODY TARGETED FLUORESCENT IN-SITU HYBRIDIZATION (CAT-FISH)July 2017November 2019Abandon2801NoNo
15643860RAPID THERMOCYCLER SYSTEM FOR RAPID AMPLIFICATION OF NUCLEIC ACIDS AND RELATED METHODSJuly 2017July 2019Abandon2410NoNo
15634874METHODS FOR MOLECULAR DETECTIONJune 2017July 2019Abandon2410NoNo
15595353METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATIONMay 2017May 2019Allow2410NoNo
15519133ONE-STOP TREATMENT METHOD FOR BREAKING NUCLEIC ACID BY MEANS OF TRANSPOSASE, AND REAGENTApril 2017August 2019Abandon2821NoNo
15424830MAPPING THE SPATIAL LOCALIZATION OF CELLULAR NUCLEIC ACIDS BY PROXIMITY-DEPENDENT ENZYMATIC TAGGINGFebruary 2017July 2020Abandon4120NoNo
15417736METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATIONJanuary 2017June 2019Allow2810NoNo
15319422DETECTION OF A SOURCE OF PINK DISCOLORATION DEFECT IN A SAMPLEDecember 2016August 2019Abandon3211NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHUNDURU, SURYAPRABHA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
31
Examiner Affirmed
13
(41.9%)
Examiner Reversed
18
(58.1%)
Reversal Percentile
82.7%
Higher than average

What This Means

With a 58.1% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
117
Allowed After Appeal Filing
29
(24.8%)
Not Allowed After Appeal Filing
88
(75.2%)
Filing Benefit Percentile
34.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CHUNDURU, SURYAPRABHA - Prosecution Strategy Guide

Executive Summary

Examiner CHUNDURU, SURYAPRABHA works in Art Unit 1637 and has examined 711 patent applications in our dataset. With an allowance rate of 33.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner CHUNDURU, SURYAPRABHA's allowance rate of 33.5% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHUNDURU, SURYAPRABHA receive 2.79 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHUNDURU, SURYAPRABHA is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +31.5% benefit to allowance rate for applications examined by CHUNDURU, SURYAPRABHA. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.1% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 26.7% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 62.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.3% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 54.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.5% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.